Ryckelynck J P, Hurault de Ligny B, Levaltier B, Cardineau E, Le Goff C, Batho J M
Service de néphrologie-hémodialyse, Centre hospitalier universitaire Clémenceau, Caen.
Nephrologie. 1995;16(1):85-92.
Chronic peritoneal dialysis, especially continuous ambulatory peritoneal dialysis, is now a modality of treatment for patients with end stage renal failure. The proportion of patients varies considerably from country to country. Non medical considerations seem to be the main reason for the limited development of the treatment modality. Most of available reports point out no difference in patient or technique survivals on hemodialysis or peritoneal dialysis. Age, diabetes mellitus, cardiovascular diseases, infections complications (peritonitis and exit-site infections) impact on mortality and morbidity (number of hospital days per patient per year). The probability of death or dropout is much higher for patients with diabetes and patients in older age groups. Most patients with end stage renal failure, especially those waiting for a kidney transplant, are suitable for peritoneal dialysis.
慢性腹膜透析,尤其是持续性非卧床腹膜透析,现已成为终末期肾衰竭患者的一种治疗方式。各国接受该治疗方式的患者比例差异很大。非医学因素似乎是该治疗方式发展受限的主要原因。大多数现有报告指出,血液透析和腹膜透析在患者生存率或技术生存率方面并无差异。年龄、糖尿病、心血管疾病、感染并发症(腹膜炎和出口处感染)会影响死亡率和发病率(每年每位患者的住院天数)。糖尿病患者和老年患者死亡或退出治疗的可能性要高得多。大多数终末期肾衰竭患者,尤其是那些等待肾移植的患者,适合进行腹膜透析。